Absence of interactive effects of trans-1,2-Cyclohexanediol, a major metabolite of the side-chain of candesartan cilexetil, in digoxin-induced arrhythmias in dogs

Journal of Pharmacological Sciences

Volumn 92, Issue 4, 2003, Pages 387-399

  Yamamoto, Keiji ^a   Kitayoshi, Takahito ^a   Nishimura, S ^a   Chatani, Fumio ^a   Watanabe, Toshifumi ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Arrhythmia; Candesartan cilexetil; Congestive heart failure; Digoxin; Dog

Indexed keywords

1,2 CYCLOHEXANEDIOL DERIVATIVE; CANDESARTAN HEXETIL; CARDIAC GLYCOSIDE; DIGOXIN; DRUG METABOLITE; OUABAIN; PENTOBARBITAL; PHENOBARBITAL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG STRUCTURE; ELECTROCARDIOGRAM; GUINEA PIG; HEART PAPILLARY MUSCLE; HEART PROARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; IN VITRO STUDY; IN VIVO STUDY; INCIDENCE; MALE; MUSCLE ACTION POTENTIAL; NONHUMAN;

EID: 0043196977     PISSN: 13478613     EISSN: None     Source Type: Journal    
DOI: 10.1254/jphs.92.387     Document Type: Article

References (47)

1. Inada Y, Naka T. Candesartan cilexetil: Pharmacological properties and protective effects against organ damage of a novel nonpeptide angiotensin II-receptor antagonist. Folia Pharmacol Jpn (Nippon Yakurigaku Zasshi). 2000;115:151-160. text in Japanese with English abstract.
2. Yoshimura M, Yasue H. Hemodynamic and hormonal effects of the angiotensin II antagonist, candesartan cilexetil, in patients with congestive heart failure. Cardiology. 2000;93:175-182.
3. Azuma J. Bioequivalence studies of candesartan cilexetil tablets. J Clin Ther Med. 1996;12:2039-2052. text in Japanese with English abstract.
4. Sever PS. Key features of candesartan cilexetil and a comparison with other angiotensin II receptor antagonists. J Hum Hypertens. 1999;13 Suppl 1:S3-S10.
5. McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation. 1999;100:1056-1064.
6. Riegger GA, Bouzo H, Petr P, et al. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH) Investigators. Circulation. 1999;100:2224-2230.
7. Aronow WS. Therapy of congestive heart failure in elderly persons. Compr Ther. 1997;23:639-647.
8. Babich M, Hamann SR, McAllister RG Jr., Pratap Reddy C, Piascik MT. Effects of verapamil on the arrhythmogenic action of acetylstrophanthidin. Pharmacology. 1984;29:224-232.
9. Bush LR, Evans RM, Gaul SL, D'Alonzo AJ. Comparative effects of verapamil, diltiazem and felodipine during experimental digitalis-induced arrhythmias. Pharmacology. 1987;34:111-120.
10. Haruno A, Matsuzaki T, Hashimoto K. Antiarrhythmic effects of optical isomers of cibenzoline on canine ventricular arrhythmias. J Cardiovasc Pharmacol. 1990;16:376-382.
11. Hashimoto K, Akiyama K, Mitsuhashi H. Antiarrhythmic effect of a new class 1 antiarrhythmic drug, nicainoprol, on canine ventricular arrhythmias. Jpn J Pharmacol. 1989;49:245-254.
12. Hashimoto K, Sugiyama A, Haruno A, Matsuzaki T, Hirasawa A. Effects of a new antiarrhythmic drug TYB-3823 on canine ventricular arrhythmia models. J Cardiovasc Pharmacol. 1991;17:336-342.
13. Helke CJ, Quest JA, Gillis RA. Effects of serotonin antagonists on digitalis-induced ventricular arrhythmias. Eur J Pharmacol. 1978;47:443-449.
14. Kao A, Kriett JM, Tobler HG, et al. Bromocriptine treatment of digitalis-induced ventricular tachyarrhythmias: Studies in a canine model. J Am Coll Cardiol. 1984;4:1188-1194.
15. Fleming JT, Holl JE. Centrally mediated enhancement of ouabain cardiotoxicity by angiotensin II in dogs. Eur J Pharmacol. 1982;85:259-268.
16. Hall RJ, Gelbart A, Silverman M, Goldman RH. Studies on digitalis-induced arrhythmias in glucose- and insulin-induced hypokalemia. J Pharmacol Exp Ther. 1977;201:711-722.
17. Hall RJ, Gelbart A, Billingham M, Snidow G, Goldman RH. Effect of chronic potassium depletion on digitalis-induced inotropy and arrhythmias. Cardiovasc Res. 1981;15:98-107.
18. Okunishi H, Kakizoe E, Shimomura K, Wang D. Cyclohexandiols, the metabolites of ester side-chain of candesartan cilexetil (TCV-116), provoke digoxin arrhythmia in heart failure dogs. J Tox Sci. 1999;24:312.
19. Okunishi H, Shimoura K, Wang D, Kakizoe E. Cardiotoxic interaction of metabolites from a prodrug segment cilexetil (cyclohexyloxy-carbonyloxy-ethyl) with digoxin in the canine failing heart. Pharmacol Res. 2002;46:301-310.
20. Singh BN, Kehoe R, Woosley RL, Scheinman M, Quart B. Multicenter trial of sotalol compared with procainamide in the suppression of inducible ventricular tachycardia: A double-blind, randomized parallel evaluation. Sotalol Multicenter Study Group. Am Heart J. 1995;129:87-97.
21. Hysing ES, Chelly JE, Doursout M-F, Merin RG. Comparative effects of halothane, enflurane, and isoflurane at equihypotensive doses on cardiac performance and coronary and renal blood flows in chronically instrumented dogs. Anesthesiology. 1992;76:979-984.
22. Pagel PS, Hettrick DA, Warltier DC. Amrinone enhances myocardial contractility and improves left ventricular diastolic function in conscious and anesthetized chronically instrumented dogs. Anesthesiology. 1993;79:753-765.
23. El-Sherif N. Electrophysiologic mechanisms of ventricular arrhythmias. Int J Card Imaging. 1991;71:141-150.
24. Thames MD, Miller BD, Abboud FM. Sensitization of vagal cardiopulmonary baroreflex by chronic digoxin. Am J Physiol. 1982;243:H815-H818.
25. Reiffel JA, Bigger JT Jr, Cramer M. Effects of digoxin on sinus nodal function before and after vagal blockade in patients with sinus nodal dysfunction: A clue to the mechanisms of the action of digitalis on the sinus node. Am J Cardiol. 1979;43:983-989.
26. Hashimoto K, Motomura S, Iijima T, Taira N. Effects of ouabain on atrioventricular conduction: Simultaneous observation in the isolated AV node preparation and the in situ heart of the dog. Tohoku J Exp Med. 1980;132:245-249.
27. Lang J, Timour Chah Q, El Chebly M, Faucon G. Modification of atrioventricular conduction under the combined influence of a cardiac glycoside and a calcium antagonist in the dog. J Pharmacol. 1986;17:275-285.
28. Roden DM. Antiarrhythmic drugs. In: Gilman A, Hardman JG, Limbird LE, editors. Goodman & Gilman's the Pharmacological Basis of Therapeutics. Chapter 35. New York: McGraw-Hill Companies, Inc.; 1996. p. 839-874.
29. Kozhevnikov DO, Yamamoto K, Robotis D, Restivo M, El-Sherif N. Electrophysiological mechanism of enhanced susceptibility of hypertrophied heart to acquired torsade de pointes arrhythmias: Tridimensional mapping of activation and recovery patterns. Circulation. 2002;105:1128-1134.
30. Kr channel blocker sematilide on the relationship between ventricular repolarization, refractoriness and onset of torsades de pointes. Jpn J Pharmacol. 2002;88:414-421.
31. Yamamoto K, Tamura T, Imai R, Yamamoto M. Acute canine model for drug-induced torsades de pointes in drug safety evaluation-influences of anesthesia and validation with quinidine and astemizole. Toxicol Sci. 2001;60:165-176.
32. Barbey JT, Lazzara R, Zipes DP. Spontaneous adverse event reports of serious ventricular arrhythmias, QT prolongation, syncope, and sudden death in patients treated with cisapride. J Cardiovasc Pharmacol Ther. 2002;7:65-76.
33. Owens RC Jr, Ambrose PG. Torsades de pointes associated with fluoroquinolones. Pharmacotherapy. 2002;22:663-668.
34. Shimizu W, Antzelevitch C. Cellular basis for the ECG features of the LQT1 form of the long-QT syndrome: Effects of beta-adrenergic agonists and antagonists and sodium channel blockers on transmural dispersion of repolarization and torsade de pointes. Circulation. 1998;98:2314-2322.
35. Chinushi M, Restivo M, Caref EB, El-Sherif N. Electrophysiological basis of arrhythmogenicity of QT/T alternans in the long-QT syndrome: Tridimensional analysis of the kinetics of cardiac repolarization. Circ Res. 1998;83:614-628.
36. + channel opener to reduce transmural dispersion of repolarization and prevent torsade de pointes in LQT1, LQT2, and LQT3 models of the long-QT syndrome. Circulation. 2000;102:706-712.
37. Satoh Y, Sugiyama A, Tamura K, Hashimoto K. Effects of mexiletine on the canine cardiovascular system complicating cisapride overdose: Potential utility of mexiletine for the treatment of drug-induced long QT syndrome. Jpn J Pharmacol. 2000;83:327-334.
38. Chezalviel-Guilbert F, Deplanne V, Davy JM, et al. Combination of sotalol and quinidine in a canine model of torsades de pointes: No increase in the QT-related proarrhythmic action of sotalol. J Cardiovasc Electrophysiol. 1998;9:498-507.
39. Kocic I, Korolkiewicz KZ. Digoxin effects in the guinea pig heart: Interaction with rimalkalim. Pharmacol Res. 1998;37:67-73.
40. Gallagher JD. Effects of isoflurane on ouabain toxicity in canine Purkinje fibers. Comparison with halothane. Anesthesiology. 1994;81:1500-1510.
41. Saner HE, Lange HW, Pierach CA, Aeppli DM. Relation between serum digoxin concentration and the electrocardiogram. Clin Cardiol. 1988;11:752-756.
42. Warner NJ, Barnard JT, Bigger JT Jr. Tissue digoxin concentrations and digoxin effect during the quinidine-digoxin interaction. J Am Coll Cardiol. 1985;5:680-686.
43. Hedman A, Meijer DK. Stereoselective inhibition by the diastereomers quinidine and quinine of uptake of cardiac glycosides into isolated rat hepatocytes. J Pharm Sci. 1998;87:457-461.
44. Woodland C, Ito S, Koren G. A model for the prediction of digoxin-drug interactions at the renal tubular cell level. Ther Drug Monit. 1998;20:134-138.
45. Jonkman JH, Van Lier JJ, Van Heiningen PN, Lins R, Sennewald R, Hogemann A. Pharmacokinetic drug interaction studies with candesartan cilexetil. J Hum Hypertens. 1997;11 Suppl 2:S31-S35.
46. Mraz J, Galova E, Nohova H, Vitkova D. 1,2- and 1,4-Cyclohexanediol: Major urinary metabolites and biomarkers of exposure to cyclohexane, cyclohexanone, and cyclohexanol in humans. Int Arch Occup Environ Health. 1998;71:560-565.
47. Mraz J, Galova E, Nohova H, Vitkova D, Tichy M. Effect of ethanol on the urinary excretion of cyclohexanol and cyclohexanediols, biomarkers of the exposure to cyclohexanone, cyclohexane and cyclohexanol in humans. Scand J Work Environ Health. 1999;25:233-237.